Akèy › Kansè nan tete › New Mexico › Albuquerque
Etid klinik pou Kansè nan tete nan Albuquerque, NM
17 etid pou Kansè nan tete ap chèche patisipan nan sit nan ak bò kote Albuquerque (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Ap rekriteFaz 3
- Presbyterian Medical Group, Albuquerque
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Lovelace Medical Center-Saint Joseph Square, Albuquerque
- University of New Mexico Cancer Center, Albuquerque
- Lovelace Women's Hospital, Albuquerque
- ak 1 plis
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Ap rekriteFaz 2
- The University of New Mexico, Albuquerque
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Ap rekriteFaz 3
- Presbyterian Kaseman Hospital ( Site 0072), Albuquerque
- University of New Mexico Comprehensive Cancer Center ( Site 0047), Albuquerque
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Ap rekriteFaz 3
- Research Site, Albuquerque
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
Ap rekriteFaz 3
- Lovelace Medical Center - Saint Joseph Square, Albuquerque
- Lovelace Women's Hospital, Albuquerque
- Presbyterian Kaseman Hospital, Albuquerque
- ak 1 plis
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Ap rekrite
- New Mexico Oncology & Hematology Consultants, Albuquerque
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Ap rekriteFaz 3
- Exigent Research LLC/New Mexico Oncology Hematology Consultants Ltd., Albuquerque
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Ap rekriteFaz 1/2
- Research Site, Albuquerque
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Ap rekriteFaz 3
- University of New Mexico Cancer Center, Albuquerque
- Presbyterian Kaseman Hospital, Albuquerque
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Ap rekriteFaz 3
- Presbyterian Kaseman Hospital, Albuquerque
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Ap rekriteFaz 3
- University of New Mexico Cancer Center, Albuquerque
SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers
Ap rekrite
- University of New Mexico, Albuquerque
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Ap rekriteEtid obsèvasyon
- Lovelace Medical Center-Saint Joseph Square, Albuquerque
- University of New Mexico Cancer Center, Albuquerque
- Lovelace Women's Hospital, Albuquerque
- ak 1 plis
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Albuquerque
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Ap rekriteFaz 3
- University of New Mexico Cancer Center, Albuquerque
BostonGene and Exigent Genomic INsight Study
Ap rekriteEtid obsèvasyon
- New Mexico Cancer Center, Albuquerque
Etid Kansè nan tete nan lòt vil
- New York City, NY136 etid
- Houston, TX126 etid
- Boston, MA112 etid
- Nashville, TN81 etid
- Los Angeles, CA73 etid
- Edison, NJ68 etid
- St. Louis, MO64 etid
- Queens, NY64 etid
- Durham, NC64 etid
- Chicago, IL59 etid
- Philadelphia, PA56 etid
- Dallas, TX55 etid
Lòt etid nan Albuquerque
- Kansè Poumon ki pa ti selil18 etid
- Kansè ovè15 etid
- Kansè (tout kalite)14 etid
- Kansè poumon14 etid
- Kansè Metastatik12 etid
- Kansè Endomèt12 etid
- Dyabèt Tip 211 etid
- Maladi kadyovaskilè10 etid
- Melanom9 etid
- Leksemi mieloïd egi9 etid
- Kansè pwostat9 etid
- Maladi ren kwonik8 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.